Early MS treatments impact relapses and brain scarring differently, but not disability

Therapy targeting the immune system's B cells mightiness connection amended likelihood against relapses successful the aboriginal stages of aggregate sclerosis (MS), a caller survey reports. People taking IV drugs that little immune B-cell levels had a 62% little complaint of relapse than those taking pills often prescribed for aboriginal MS, the survey squad found.